View Filing Data

DOCUMENT AND ENTITY INFORMATION - shares	9 Months Ended
DOCUMENT AND ENTITY INFORMATION - shares	Dec. 31, 2016	Feb. 02, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--04-01
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,004,300

CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015
Income Statement [Abstract]
Net revenues	$ 227,841	$ 233,384	$ 658,050	$ 666,490
Cost of goods sold	126,762	124,529	361,667	349,799
Gross profit	101,079	108,855	296,383	316,691
Operating expenses:
Research and development	8,462	10,942	28,235	33,816
Selling, general and administrative	70,956	78,940	228,639	240,946
Impairment of assets	449	85,048	1,384	85,048
Contingent consideration income	0	(4,898)	0	(4,727)
Total operating expenses	79,867	170,032	258,258	355,083
Operating income (loss)	21,212	(61,177)	38,125	(38,392)
Interest and other expense, net	(2,275)	(2,141)	(6,414)	(6,756)
Income (loss) before provision (benefit) for income taxes	18,937	(63,318)	31,711	(45,148)
Provision (benefit) for income taxes	3,544	(3,878)	6,839	1,696
Net income (loss)	$ 15,393	$ (59,440)	$ 24,872	$ (46,844)
Net earnings (loss) per share - basic (in dollars per share)	$ 0.30	$ (1.17)	$ 0.48	$ (0.92)
Net earnings (loss) per share - diluted (in dollars per share)	$ 0.30	$ (1.17)	$ 0.48	$ (0.92)
Weighted average shares outstanding
Basic (in shares)	51,708	50,741	51,369	50,927
Diluted (in shares)	52,103	50,741	51,671	50,927
Comprehensive income (loss)	$ 13,084	$ (62,316)	$ 20,888	$ (66,469)

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Apr. 02, 2016
Current assets:
Cash and cash equivalents	$ 129,639	$ 115,123
Accounts receivable, less allowance of $2,656 at December 31, 2016 and $2,253 at April 2, 2016	150,557	157,093
Inventories, net	188,489	187,028
Prepaid expenses and other current assets	27,877	28,842
Total current assets	496,562	488,086
Property, plant and equipment, net	335,957	337,634
Intangible assets, less accumulated amortization of $206,444 at December 31, 2016 and $190,816 at April 2, 2016	185,427	204,458
Goodwill	267,314	267,840
Deferred tax asset, long-term	7,575	7,055
Other long-term assets	13,586	14,055
Total assets	1,306,421	1,319,128
Current liabilities:
Notes payable and current maturities of long-term debt	66,271	43,471
Accounts payable	48,848	39,674
Accrued payroll and related costs	41,556	35,798
Other liabilities	59,546	66,608
Total current liabilities	216,221	185,551
Long-term debt, net of current maturities	269,997	364,529
Deferred tax liability, long-term	24,463	21,377
Other long-term liabilities	24,843	26,106
Total stockholders’ equity
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,825,961 shares at December 31, 2016 and 50,932,348 shares at April 2, 2016	518	509
Additional paid-in capital	468,348	439,912
Retained earnings	341,056	316,184
Accumulated other comprehensive loss	(39,025)	(35,040)
Total stockholders’ equity	770,897	721,565
Total liabilities and stockholders’ equity	$ 1,306,421	$ 1,319,128

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2016	Apr. 02, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 2,656	$ 2,253
Intangible assets, amortization	$ 206,444	$ 190,816
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,825,961	50,932,348
Common stock, shares outstanding (in shares)	51,825,961	50,932,348

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ 24,872	$ (46,844)
Non-cash items:
Depreciation and amortization	67,531	67,721
Impairment of assets	3,413	85,048
Provision for losses on accounts receivable and inventory	11,398	4,055
Stock-based compensation expense	6,608	6,199
Deferred tax benefit	0	(7,088)
Unrealized loss (gain) from hedging activities	331	(2,867)
Changes in fair value of contingent consideration	0	(4,727)
Other non-cash operating activities	885	862
Change in operating assets and liabilities:
Change in accounts receivable	3,878	(4,186)
Change in inventories	(13,960)	2,791
Change in prepaid income taxes	868	997
Change in other assets and other liabilities	(996)	6,622
Change in accounts payable and accrued expenses	20,333	(39,971)
Net cash provided by operating activities	125,161	68,612
Cash Flows from Investing Activities:
Capital expenditures	(60,517)	(73,871)
Proceeds from sale of property, plant and equipment	1,773	397
Other acquisitions and investments	0	(3,000)
Net cash used in investing activities	(58,744)	(76,474)
Cash Flows from Financing Activities:
Net (decrease) increase in short-term loans	(40,975)	7,143
Repayment of term loan borrowings	(30,827)	(7,114)
Proceeds from employee stock purchase plan	3,560	4,340
Proceeds from exercise of stock options	18,278	10,489
Share repurchases	0	(60,984)
Payments on long-term real estate mortgage	0	(845)
Net cash used in financing activities	(49,964)	(46,971)
Effect of exchange rates on cash and cash equivalents	(1,937)	(662)
Net Change in Cash and Cash Equivalents	14,516	(55,495)
Cash and Cash Equivalents at Beginning of Period	115,123	160,662
Cash and Cash Equivalents at End of Period	129,639	105,167
Supplemental Disclosures of Cash Flow Information:
Interest paid	6,058	6,206
Income taxes paid	5,724	5,884
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 5,081	$ 9,259

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Basis of Presentation Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the nine months ended December 31, 2016 are not necessarily indicative of the results that may be expected for the full fiscal year ending April 1, 2017, or any other interim period. Operating results for the nine months ended December 26, 2015 include the correction of an understatement of the provision for income taxes in fiscal 2015, as well as the correction of an overstated liability in fiscal 2014, both of which were determined to be immaterial to all periods impacted. Absent these corrections, our net income for the nine months ended December 26, 2015 would have been $1.1 million lower than the amount included in the accompanying Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended April 2, 2016. We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Refer to Note 9, Debt, for information pertaining to a debt payment that was made after the balance sheet date but prior to the issuance of the financial statements. There were no other subsequent events identified.

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Dec. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Standards Implemented In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU No. 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. We adopted ASU No. 2014-12 in our first quarter of fiscal 2017 using the prospective method. The adoption of ASU No. 2014-12 did not have a material effect on our financial position or results of operations. In August 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), Health and Welfare Benefit Plans (Topic 965): (Part I) Fully Benefit-Responsive Investment Contracts, (Part II) Plan Investment Disclosures, (Part III) Measurement Date Practical Expedient. Part I of ASU No. 2015-12 designates contract value as the only required measure for fully benefit-responsive investment contracts. Part II simplifies the investment disclosure requirements under Topics 820, 960, 962, and 965 for employee benefits plans and Part III provides a measurement date practical expedient for fiscal periods that do not coincide with a month-end date. ASU No. 2015-12 was effective for fiscal years beginning after December 15, 2015 with early adoption permitted. The adoption of ASU No. 2015-12 did not have a material effect on our financial position or results of operations.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

EARNINGS PER SHARE ("EPS")

9 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



	Three Months Ended					Nine Months Ended
(In thousands, except per share amounts)	December 31, 2016		December 26, 2015			December 31, 2016		December 26, 2015
Basic EPS
Net income (loss)	$	15,393	$	(59,440	)	$	24,872	$	(46,844	)
Weighted average shares	51,708		50,741			51,369		50,927
Basic income (loss) per share	$	0.30	$	(1.17	)	$	0.48	$	(0.92	)
Diluted EPS
Net income (loss)	$	15,393	$	(59,440	)	$	24,872	$	(46,844	)
Basic weighted average shares	51,708		50,741			51,369		50,927
Net effect of common stock equivalents	395		—			302		—
Diluted weighted average shares	52,103		50,741			51,671		50,927
Diluted income (loss) per share	$	0.30	$	(1.17	)	$	0.48	$	(0.92	)

Basic earnings per share is calculated using our weighted-average outstanding common shares. Diluted earnings per share is calculated using our weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method. For the three and nine months ended December 31, 2016, weighted average shares outstanding, assuming dilution, excludes the impact of 1.1 million and 1.7 million anti-dilutive shares, respectively. For the three and nine months ended December 26, 2015, we recognized a net loss; therefore we excluded the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect.

PRODUCT WARRANTIES

9 Months Ended

Dec. 31, 2016

Product Warranties Disclosures [Abstract]

PRODUCT WARRANTIES

We generally provide warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.



	Nine Months Ended
(In thousands)	December 31, 2016			December 26, 2015
Warranty accrual as of the beginning of the period	$	420		$	531
Warranty provision	860			532
Warranty spending	(1,077		)	(701		)
Warranty accrual as of the end of the period	$	203		$	362

INVENTORIES

9 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.



(In thousands)	December 31, 2016		April 2, 2016
Raw materials	$	56,729	$	62,062
Work-in-process	10,202		13,180
Finished goods	121,558		111,786
Total inventories	$	188,489	$	187,028

Inventories include specific charges and reserves of $4.5 million and $9.0 million for the three and nine months ended December 31, 2016, respectively, primarily related to the impact of the whole blood product recall and changes in demand for Blood Center products.

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill Impairment During fiscal 2016, as a result of an interim impairment test, we determined that the estimated fair value of all of our reporting units exceeded their respective carrying values, with the exception of Europe, Middle East and Africa (collectively "EMEA"), for which we recorded a goodwill impairment charge of $66.3 million during the third quarter of fiscal 2016. As of that test date, the reporting unit that was most at risk of impairment in future periods was the Americas Blood Center and Hospital, which had an excess fair value over carrying value of approximately 25.8% and allocated goodwill of $175.9 million. We believe that our assumptions used to determine the fair value of the Americas Blood Center and Hospital reporting unit were reasonable. If different assumptions were to be used, particularly with respect to estimating future cash flows, or if actual operating results and cash flows of the Americas Blood Center and Hospital differ from the estimated operating results and related cash flows, there is the potential that an impairment charge could result in future periods. Additionally, changes to the discount rate or the long-term growth rate could also give rise to an impairment in future periods. During the third quarter of fiscal 2017, there were no new or additional impairment indicators associated with this reporting unit. We will complete our annual impairment testing during the fourth quarter of fiscal 2017. Intangible Asset Impairment In April 2013, we acquired a patented red cell storage solution, referred to as SOLX, from Hemerus Medical, LLC for cash consideration plus an agreement to make certain future payments accounted for as contingent consideration. During the third quarter of fiscal 2016, we received U.S. Food and Drug Administration clearance for the SOLX solution with a Haemonetics whole blood filter. At that time, the vast majority of the U.S. market utilized a red cell filter, not a whole blood filter, for whole blood collection procedures as they seek to optimize blood component yield from each collection. To bring SOLX to market with a red cell filter would have required substantial additional investment. Accordingly, we conducted a final market review prior to proceeding with this investment, which indicated customers would not pay a price for a SOLX collection kit sufficient to recover the cost to produce it, or to provide an adequate return on the additional investment. As result, during the third quarter of fiscal 2016, we suspended further investment in the SOLX technology and recorded an impairment charge of $18.7 million to write down the carrying value of the SOLX intangible assets. In addition, we reversed the $4.9 million of contingent consideration liability we had recorded, as we do not expect to achieve the conditions that called for its payment. Refer to Note 10, Commitments and Contingencies, for further discussion of the arbitration resulting from a dispute over the payment of this contingent consideration as well as certain royalty payments. Intangible asset impairment charges during the three and nine months ended December 31, 2016 were $0.4 million and $1.9 million, respectively, and primarily related to the impairment of certain capitalized software as discussed in Note 13, Capitalization of Software.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS

9 Months Ended

Dec. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the nine months ended December 31, 2016, 40.0% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of December 31, 2016 and April 2, 2016 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income (Loss) until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $99.0 million as of December 31, 2016 and $107.4 million as of April 2, 2016. At December 31, 2016, gains of $1.2 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of December 31, 2016 mature within twelve months.

Non-Designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $49.7 million as of December 31, 2016 and $48.8 million as of April 2, 2016.

Interest Rate Swaps

On December 21, 2012, we entered into two interest rate swap agreements (the "Swaps") on a total notional amount of $250.0 million of debt. The Swaps are amortizing and mature on August 1, 2017. We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. As of December 31, 2016, the notional amount of these Swaps was $150.0 million. For three and nine months ended December 31, 2016 and December 26, 2015, we recorded nominal activity in Accumulated Other Comprehensive Loss to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income (loss) and comprehensive income (loss) for the nine months ended December 31, 2016:



(In thousands)	Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Income (Loss)		Amount of (Loss) Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings			Location in Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	Amount of Gain (Loss) Excluded from Effectiveness Testing *		Location in Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Designated foreign currency hedge contracts, net of tax	$	1,517	$	(4,678	)	Net revenues, COGS, and SG&A	$	388	Interest and other expense, net
Non-designated foreign currency hedge contracts	—		—				1,031		Interest and other expense, net
Designated interest rate swaps, net of tax	$	165	$	—		Interest and other expense, net	$	—

* We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

We did not have fair value hedges or net investment hedges outstanding as of December 31, 2016 or April 2, 2016. As of December 31, 2016, no deferred tax assets were recognized for designated foreign currency hedges.

ASC Topic 815 requires all derivative instruments to be recognized at their fair value as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 31, 2016, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 31, 2016 and April 2, 2016:



(In thousands)	Location in Balance Sheet	As of December 31, 2016		As of April 2, 2016
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	3,255	$	427
Designated interest rate swaps	Other current assets	69		—
		$	3,324	$	427
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,916	$	4,056
Designated interest rate swaps	Other current liabilities	—		154
		$	1,916	$	4,210

Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 31, 2016 and April 2, 2016.



	As of December 31, 2016
(In thousands)	Level 1		Level 2		Total
Assets
Money market funds	$	79,452	$	—	$	79,452
Designated foreign currency hedge contracts	$	—	$	3,255	$	3,255
Designated interest rate swaps			$	69	$	69
	$	79,452	$	3,324	$	82,776
Liabilities
Designated foreign currency hedge contracts	$	—	$	1,916	$	1,916
	$	—	$	1,916	$	1,916

	As of April 2, 2016
	Level 1		Level 2		Total
Assets
Money market funds	$	72,491	$	—	$	72,491
Designated foreign currency hedge contracts	—		427		427
Designated interest rate swaps	$	72,491	$	427	$	72,918

Liabilities
Designated foreign currency hedge contracts	$	—	$	4,056	$	4,056
Designated interest rate swaps	—		154		154
	$	—	$	4,210	$	4,210

For the nine months ended December 31, 2016, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above table.

Other Fair Value Disclosures

The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

INCOME TAXES

9 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

We conduct business globally and report our results of operations in a number of foreign jurisdictions in addition to the United States. Our reported tax rate is generally lower than the U.S. federal statutory rate as the income tax rates in the foreign jurisdictions in which we operate are generally lower than the U.S. statutory tax rate.

During the three months ended December 31, 2016 and December 26, 2015, we reported an income tax provision of $3.5 million and an income tax benefit of $3.9 million, respectively, representing effective tax rates of 18.7% and 6.1%, respectively. For the nine months ended December 31, 2016 and December 26, 2015 we reported an income tax provision of $6.8 million and $1.7 million, respectively, representing effective tax rates of 21.6% and (3.8)%, respectively.

The increase in our income tax provision for both the three and nine months ended December 31, 2016, as compared to the prior year periods, was primarily due to the impact of impairment charges recorded during the three months ended December 26, 2015 and changes in the jurisdictional mix of earnings. During the three and nine months ended December 26, 2015, we recorded goodwill impairment charges of $66.3 million and intangible asset impairment charges of $18.7 million with a corresponding $7.1 million benefit to income taxes. The income tax provision for the nine months ended December 26, 2015 includes a discrete tax provision of $1.0 million to increase the deferred tax liability related to amortizable goodwill as a result of the statutory capital gains tax rate in Puerto Rico increasing from 15% to 20%.

For the nine months ended December 31, 2016, the income tax provision includes a discrete tax provision of $1.4 million for an uncertain tax position that was triggered by a reduction in workforce in one of our foreign subsidiaries during the first quarter of fiscal 2017. This discrete tax provision is inclusive of an insignificant amount of interest. We had previously negotiated a tax holiday under which we were required to maintain certain levels of headcount for a multi-year period. During the first quarter of fiscal 2017, as a result of a reduction in workforce, we were unable to satisfy the required headcount levels and became subject to a potential tax assessment related to historical tax years. The tax provision associated with this tax reserve establishment was partially offset by a tax benefit of $0.5 million for the release of tax reserves due to the expiration of statutes of limitations during the second and third quarters of fiscal 2017.

We are in a three year cumulative loss position in the U.S. and, accordingly, maintain a valuation allowance against our U.S. deferred tax assets. We also maintain a valuation allowance against certain foreign deferred tax assets which we have concluded are not more-likely-than-not realizable.

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of December 31, 2016 we had $3.4 million of unrecognized tax benefits, of which $1.5 million would impact the effective tax rate, if recognized. As of April 2, 2016, we had $2.5 million of unrecognized tax benefits, of which $0.6 million would impact the effective tax rate, if recognized.

During the nine months ended December 31, 2016, our unrecognized tax benefits were increased by $1.3 million due to the establishment of a tax reserve for the potential tax assessment discussed above.

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal periods ended December 31, 2016 and April 2, 2016:



(In thousands)	Nine Months Ended December 31, 2016			Year Ended April 2, 2016
Beginning balance	$	2,523		$	7,070
Additions for tax positions of prior years	1,260			340
Reductions of tax positions	—			(4,158		)
Closure of statute of limitations	(403		)	(729		)
Ending balance	$	3,380		$	2,523

As of December 31, 2016, we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $1.3 million in the next twelve months, as a result of closure of various statutes of limitations or settlements.

Our historic practice has been and continues to be to recognize interest and penalties related to Federal, state and foreign income tax matters in income tax expense. Approximately $0.4 million of gross interest and penalties were accrued at December 31, 2016 and April 2, 2016 and is not included in the amounts above. Tax expense associated with accrued interest and penalties was insignificant for the nine months ended December 31, 2016.

We conduct business globally and, as a result, file consolidated and separate Federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With a few exceptions, we are no longer subject to U.S. federal, state, or local income tax examinations for years before 2012 and foreign income tax examinations for years before 2011.

DEBT	9 Months Ended
DEBT	Dec. 31, 2016
Debt Disclosure [Abstract]
DEBT	DEBT On August 1, 2012, we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million Term Loan and a $50.0 million revolving loan (the “Revolving Credit Facility”), and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities had a term of five years and mature on August 1, 2017. Interest was based on the Adjusted LIBOR plus a range of 1.125% to 1.500% depending on achievement of leverage ratios and customary credit terms which included financial and negative covenants. On June 30, 2014, we modified our existing Credit Facilities by extending the maturity date to July 1, 2019, extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. In addition, the amended Credit Agreement provides for a $100.0 million revolving credit facility and establishes interest rates in the range of LIBOR plus 1.125% – 1.500%, depending on certain conditions. No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of $337.2 million as of December 31, 2016. During the three and nine months ended December 31, 2016, we paid $11.9 million and $30.8 million in principal repayments, respectively, for the Term Loan. During the three and nine months ended December 31, 2016, we reduced our borrowings on the Revolving Credit Facility by $40.0 million as part of our normal cash management process. In addition, on January 31, 2017, we reduced our borrowings on the Revolving Credit Facility by the remaining $10.0 million that was outstanding. We were in compliance with the leverage and interest coverage ratios specified in the Credit Agreement as well as all other bank covenants as of December 31, 2016.

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES We are presently engaged in various legal actions, and although the total liability cannot be determined at the present time, based on consultation with counsel, we believe that any such liability will not materially affect our consolidated financial position or our results of operations. Italian Employment Litigation Our Italian manufacturing subsidiary is party to several actions initiated by employees of the facility in Ascoli-Piceno, Italy where we have ceased manufacturing operations. These include actions claiming (i) working conditions and minimum salaries should have been established by either a different classification under their national collective bargaining agreement or a different agreement altogether, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) payment of the extra time used for changing into and out of their working clothes at the beginning and end of each shift. In addition, a union represented in the Ascoli plant has filed an action alleging that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings. Finally, we have been added as defendants on claims filed against Pall Corporation prior to our acquisition of the plant in August 2012. These claims relate to agreements to "freeze" benefit allowances for a certain period in exchange for Pall's commitments on hiring and plant investment. The total amount of damages claimed by the plaintiffs in these matters is approximately $4.3 million. At this point in the proceedings, we believe the losses are unlikely and therefore no amounts have been accrued. In the future, we may receive other similar claims or adverse rulings from the courts which changes our judgment on these cases. SOLX Arbitration In July 2016, H2 Equity, LLC, formerly known as Hemerus Corporation, filed an arbitration claim for $17 million in milestone and royalty payments allegedly owed as part of our acquisition of the filter and storage solution business from Hemerus Medical, LLC ("Hemerus") in fiscal 2014. The acquired storage solution is referred to as SOLX. At the closing in April 2013, Haemonetics paid Hemerus a total of $24 million and agreed to a $3 million milestone payment due when the U.S. Food and Drug Administration ("FDA") approved a new indication for SOLX (the “24-Hour Approval”), using a filter acquired from Hemerus. We also agreed to make future royalty payments up to a cumulative maximum of $14 million based on the sale of products incorporating SOLX over a ten year period. Due to performance issues with the Hemerus filter, Haemonetics filed for, and received, the 24-Hour Approval using a Haemonetics filter. Accordingly, Haemonetics did not pay Hemerus the $3 million milestone payment because the 24-Hour Approval was obtained using a Haemonetics filter, not a Hemerus filter. In addition, we have not paid any royalties to date as we have not made any commercial sales of products incorporating SOLX. H2 Equity claims, in part, that we owe them $3 million for the receipt of the 24-Hour Approval despite the use of a Haemonetics filter to obtain the approval and that we have failed to make commercially reasonable efforts to market and sell products incorporating SOLX. We believe that we have meritorious defenses to these claims. It is not possible to accurately evaluate the likelihood or amount of any potential losses related to this claim and therefore no amounts have been accrued. Product Recall In June 2016, we issued a voluntary recall of certain whole blood collection kits sold to our Blood Center customers in the United States. The recall resulted from some collection sets' filters failing to adequately remove leukocytes from collected blood. Because most U.S. hospitals prefer to transfuse leukoreduced blood, our blood center customers may have conducted further tests to confirm the blood was adequately leukoreduced, sold the blood as non-leukoreduced at a lower price or discarded the blood collected using the defective sets. As a result of the recall, we have recorded total charges of $4.3 million during the nine months ended December 31, 2016, which consists of $3.7 million of charges associated with customer returns and inventory reserves and $0.6 million of charges associated with customer claims, as discussed below. We may record incremental charges in future periods. We determined that the affected sets were distributed between April and June 2016; credits have been issued to customers who returned affected sets purchased during this period. During the nine months ended December 31, 2016, we recorded charges of $3.7 million, which consisted of $2.5 million of estimated sales returns, $1.1 million of net inventory reserves for the affected collection sets on-hand that had not yet been shipped to customers and $0.1 million of freight expenses. Our estimate of sales returns was based on preliminary returns data received to date, however, actual customer returns are not expected to conclude until the fourth quarter of fiscal 2017. Additionally, we received claims from customers which comprised substantially all the affected units. These claims seek reimbursement for losses sustained as a result of the recall and total $14.6 million. We believe it is probable that we will incur expenses as a result of these claims and that our range of loss is $0.6 million to $14.6 million, however, we do not have sufficient information to develop a best estimate within this range. Accordingly, we have recorded a liability of $0.6 million, which represents the low end of the range. Incremental charges may be recorded in future periods as additional customer returns and claims data becomes available. We have insurance policies in place which may provide coverage for certain types of potential claims. We will assess the potential for insurance recoveries as we receive more information about customer claims in future reporting periods.

SEGMENT AND ENTERPRISE-WIDE INFORMATION

9 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the plasma business. We aggregate components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:


•	Japan


•	Europe, Middle East and Africa (collectively “EMEA”)


•	North America Plasma


•	All Other

The Company has aggregated the following two operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin:


•	Americas Blood Center and Hospital


•	Asia - Pacific

In periods prior to the fourth quarter of fiscal 2016, we believed a single reportable segment was consistent with its basic organizational structure and believed aggregation was consistent with its primary basis for decision making. As a result, prior year segment information has been restated to conform to the current reportable segments.

During the first quarter of fiscal 2017, management reorganized its operating segments such that certain components of All Other are now reported as components of EMEA. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2017. These changes did not have an impact on our ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and asset impairments. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year, therefore segment information is presented on this basis.

Selected information by business segment is presented below:



	Three Months Ended						Nine Months Ended
(In thousands)	December 31, 2016			December 26, 2015			December 31, 2016			December 26, 2015
Net revenues
Japan	$	20,173		$	22,709		$	53,730		$	60,212
EMEA	49,857			53,258			141,531			150,267
North America Plasma	83,324			73,378			235,091			206,427
All Other	79,884			85,218			236,315			248,217
Net revenues before foreign exchange impact	233,238			234,563			666,667			665,123
Effect of exchange rates	(5,397		)	(1,179		)	(8,617		)	1,367
Net revenues	$	227,841		$	233,384		$	658,050		$	666,490



	Three Months Ended						Nine Months Ended
(In thousands)	December 31, 2016			December 26, 2015			December 31, 2016			December 26, 2015
Segment operating income
Japan	$	9,331		$	10,013		$	24,335		$	26,643
EMEA	13,116			13,280			33,866			35,292
North America Plasma	24,660			28,445			80,209			81,909
All Other	26,441			29,682			82,406			88,156
Segment operating income	73,548			81,420			220,816			232,000
Corporate operating expenses	(38,683		)	(46,481		)	(132,550		)	(142,007		)
Effect of exchange rates	(151		)	(7		)	(790		)	3,875
Restructuring and turnaround costs	(6,762		)	(8,570		)	(27,215		)	(29,746		)
Deal amortization	(6,530		)	(7,389		)	(20,611		)	(22,193		)
Asset impairments	(210		)	(85,048		)	(1,525		)	(85,048		)
Contingent consideration income	—			4,898			—			4,727
Operating income	$	21,212		$	(61,177	)	$	38,125		$	(38,392	)

In connection with the global strategic review of our business portfolio, we organized our current products into four franchises for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these franchises, however, no other financial information is currently available on this basis.

Net revenues by franchise are as follows:



	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2016		December 26, 2015		December 31, 2016		December 26, 2015
Plasma	$	108,655	$	100,578	$	309,868	$	282,141
Blood Center	76,354		90,418		221,567		257,736
Cell Processing	25,918		27,741		77,949		83,659
Hemostasis Management	16,914		14,647		48,666		42,954
Net revenues	$	227,841	$	233,384	$	658,050	$	666,490

Net revenues generated in our principle operating regions on a reported basis are as follows:



	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2016		December 26, 2015		December 31, 2016		December 26, 2015
United States	$	136,759	$	131,664	$	393,302	$	379,390
Japan	22,319		19,482		58,949		50,406
Europe	38,892		52,453		116,865		150,610
Asia	27,749		27,755		83,125		79,878
Other	2,122		2,030		5,809		6,206
Net revenues	$	227,841	$	233,384	$	658,050	$	666,490

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

RESTRUCTURING

9 Months Ended

Dec. 31, 2016

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business.

During the first quarter of fiscal 2017, in connection with our global strategic review, we launched a restructuring program designed to reposition our organization and improve our cost structure. This program includes both a reduction of headcount and operating costs as well as projects to simplify product lines. We may also take steps to modify our manufacturing operations to align with our strategic direction.

We initially expected to incur approximately $26 million of restructuring and turnaround related costs, comprised of $17 million in termination benefits and $9 million in other related exit costs. Savings from this program were initially estimated to be approximately $40 million in fiscal 2017. During the three and nine months ended December 31, 2016, we incurred $4.1 million and $22.9 million, respectively, of restructuring and turnaround charges under this program. Additionally, during the three and nine months ended December 31, 2016, we recorded $2.6 million and $4.2 million, respectively, of restructuring and turnaround charges under a prior program. The Company continues to evaluate non-performing assets and business units as part of its turnaround, which has resulted in additional charges and benefits during fiscal 2017.

The following summarizes the restructuring activity for the nine months ended December 31, 2016:



(In thousands)	Severance and Other Employee Costs			Other Costs			Asset Write Down			Total Restructuring
Balance at April 2, 2016	$	8,752		$	—		$	—		$	8,752
Costs incurred, net of reversals	16,680			785			599			18,064
Payments	(16,301		)	(463		)	—			(16,764		)
Non-cash adjustments	—						(599		)	(599		)
Balance at December 31, 2016	$	9,131		$	322		$	—		$	9,453

Substantially all of the restructuring expenses have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of income (loss). As of December 31, 2016, we had a restructuring liability of $9.5 million, of which approximately $9.2 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, during the nine months ended December 31, 2016, we also incurred $9.1 million of costs that do not constitute as restructuring under ASC 420, which we refer to as turnaround costs. These costs consist primarily of expenditures directly related to our restructuring initiative and include program management, implementation of the global strategic review initiatives and accelerated depreciation.

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs	Three Months Ended					Nine Months Ended
(in thousands)	December 31, 2016			December 26, 2015		December 31, 2016		December 26, 2015
Japan	$	(72	)	$	—	$	764	$	9
EMEA	198			37		3,209		155
North America Plasma	1			—		369		—
All Other	1,905			3,829		13,722		18,085
Total	$	2,032		$	3,866	$	18,064	$	18,249

Turnaround costs	Three Months Ended					Nine Months Ended
(in thousands)	December 31, 2016			December 26, 2015		December 31, 2016		December 26, 2015
Japan	$	—		$	142	$	2	$	333
EMEA	(5		)	83		76		503
North America Plasma	37			—		973		—
All Other	4,674			4,295		8,036		10,769
Total	$	4,706		$	4,520	$	9,087	$	11,605

Total restructuring and turnaround costs	$	6,738		$	8,386	$	27,151	$	29,854

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	9 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Dec. 31, 2016
Research and Development [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS For costs incurred related to the development of software to be sold, leased or otherwise marketed, we apply the provisions of ASC 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $8.3 million and $12.9 million in software development costs for ongoing initiatives during the nine months ended December 31, 2016 and December 26, 2015, respectively. At December 31, 2016 and April 2, 2016, we have a total of $61.9 million and $54.9 million of capitalized software costs, respectively, of which $16.9 million and $14.4 million are related to in-process software development initiatives, respectively. During the nine months ended December 31, 2016 and December 26, 2015, $4.5 million and $6.4 million of capitalized costs were placed into service, respectively. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. We review these assets for impairment at least annually. During the nine months ended December 31, 2016, we impaired $1.3 million of capitalized software. The impairment charge is classified within cost of goods sold on our consolidated statements of income (loss).

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE LOSS

9 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of Accumulated Other Comprehensive Loss are as follows:



(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized Gain/Loss on Derivatives			Total
Balance as of April 2, 2016	$	(22,499	)	$	(7,492	)	$	(5,049	)	$	(35,040	)
Other comprehensive (loss) income before reclassifications⁽¹⁾	(10,344		)	—			1,681			(8,663		)
Amounts reclassified from Accumulated Other Comprehensive Loss⁽¹⁾	—			—			4,678			4,678
Net current period other comprehensive income (loss)	(10,344		)	—			6,359			(3,985		)
Balance as of December 31, 2016	$	(32,843	)	$	(7,492	)	$	1,310		$	(39,025	)

⁽¹⁾ Presented net of income taxes, the amounts of which are insignificant.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

EARNINGS PER SHARE ("EPS") (Tables)

9 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



	Three Months Ended					Nine Months Ended
(In thousands, except per share amounts)	December 31, 2016		December 26, 2015			December 31, 2016		December 26, 2015
Basic EPS
Net income (loss)	$	15,393	$	(59,440	)	$	24,872	$	(46,844	)
Weighted average shares	51,708		50,741			51,369		50,927
Basic income (loss) per share	$	0.30	$	(1.17	)	$	0.48	$	(0.92	)
Diluted EPS
Net income (loss)	$	15,393	$	(59,440	)	$	24,872	$	(46,844	)
Basic weighted average shares	51,708		50,741			51,369		50,927
Net effect of common stock equivalents	395		—			302		—
Diluted weighted average shares	52,103		50,741			51,671		50,927
Diluted income (loss) per share	$	0.30	$	(1.17	)	$	0.48	$	(0.92	)

PRODUCT WARRANTIES (Tables)

9 Months Ended

Dec. 31, 2016

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.



	Nine Months Ended
(In thousands)	December 31, 2016			December 26, 2015
Warranty accrual as of the beginning of the period	$	420		$	531
Warranty provision	860			532
Warranty spending	(1,077		)	(701		)
Warranty accrual as of the end of the period	$	203		$	362

INVENTORIES (Tables)

9 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.



(In thousands)	December 31, 2016		April 2, 2016
Raw materials	$	56,729	$	62,062
Work-in-process	10,202		13,180
Finished goods	121,558		111,786
Total inventories	$	188,489	$	187,028

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Dec. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



(In thousands)	Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Income (Loss)		Amount of (Loss) Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings			Location in Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	Amount of Gain (Loss) Excluded from Effectiveness Testing *		Location in Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Designated foreign currency hedge contracts, net of tax	$	1,517	$	(4,678	)	Net revenues, COGS, and SG&A	$	388	Interest and other expense, net
Non-designated foreign currency hedge contracts	—		—				1,031		Interest and other expense, net
Designated interest rate swaps, net of tax	$	165	$	—		Interest and other expense, net	$	—

* We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 31, 2016 and April 2, 2016:



(In thousands)	Location in Balance Sheet	As of December 31, 2016		As of April 2, 2016
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	3,255	$	427
Designated interest rate swaps	Other current assets	69		—
		$	3,324	$	427
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,916	$	4,056
Designated interest rate swaps	Other current liabilities	—		154
		$	1,916	$	4,210

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 31, 2016 and April 2, 2016.



	As of December 31, 2016
(In thousands)	Level 1		Level 2		Total
Assets
Money market funds	$	79,452	$	—	$	79,452
Designated foreign currency hedge contracts	$	—	$	3,255	$	3,255
Designated interest rate swaps			$	69	$	69
	$	79,452	$	3,324	$	82,776
Liabilities
Designated foreign currency hedge contracts	$	—	$	1,916	$	1,916
	$	—	$	1,916	$	1,916

	As of April 2, 2016
	Level 1		Level 2		Total
Assets
Money market funds	$	72,491	$	—	$	72,491
Designated foreign currency hedge contracts	—		427		427
Designated interest rate swaps	$	72,491	$	427	$	72,918

Liabilities
Designated foreign currency hedge contracts	$	—	$	4,056	$	4,056
Designated interest rate swaps	—		154		154
	$	—	$	4,210	$	4,210

INCOME TAXES (Tables)

9 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Unrecognized Tax Benefits Roll Forward

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal periods ended December 31, 2016 and April 2, 2016:



(In thousands)	Nine Months Ended December 31, 2016			Year Ended April 2, 2016
Beginning balance	$	2,523		$	7,070
Additions for tax positions of prior years	1,260			340
Reductions of tax positions	—			(4,158		)
Closure of statute of limitations	(403		)	(729		)
Ending balance	$	3,380		$	2,523

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

9 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Selected Information by Business Segment

Selected information by business segment is presented below:



	Three Months Ended						Nine Months Ended
(In thousands)	December 31, 2016			December 26, 2015			December 31, 2016			December 26, 2015
Net revenues
Japan	$	20,173		$	22,709		$	53,730		$	60,212
EMEA	49,857			53,258			141,531			150,267
North America Plasma	83,324			73,378			235,091			206,427
All Other	79,884			85,218			236,315			248,217
Net revenues before foreign exchange impact	233,238			234,563			666,667			665,123
Effect of exchange rates	(5,397		)	(1,179		)	(8,617		)	1,367
Net revenues	$	227,841		$	233,384		$	658,050		$	666,490



	Three Months Ended						Nine Months Ended
(In thousands)	December 31, 2016			December 26, 2015			December 31, 2016			December 26, 2015
Segment operating income
Japan	$	9,331		$	10,013		$	24,335		$	26,643
EMEA	13,116			13,280			33,866			35,292
North America Plasma	24,660			28,445			80,209			81,909
All Other	26,441			29,682			82,406			88,156
Segment operating income	73,548			81,420			220,816			232,000
Corporate operating expenses	(38,683		)	(46,481		)	(132,550		)	(142,007		)
Effect of exchange rates	(151		)	(7		)	(790		)	3,875
Restructuring and turnaround costs	(6,762		)	(8,570		)	(27,215		)	(29,746		)
Deal amortization	(6,530		)	(7,389		)	(20,611		)	(22,193		)
Asset impairments	(210		)	(85,048		)	(1,525		)	(85,048		)
Contingent consideration income	—			4,898			—			4,727
Operating income	$	21,212		$	(61,177	)	$	38,125		$	(38,392	)

Schedule of Revenues by Product Line and Geographic Regions

Net revenues by franchise are as follows:



	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2016		December 26, 2015		December 31, 2016		December 26, 2015
Plasma	$	108,655	$	100,578	$	309,868	$	282,141
Blood Center	76,354		90,418		221,567		257,736
Cell Processing	25,918		27,741		77,949		83,659
Hemostasis Management	16,914		14,647		48,666		42,954
Net revenues	$	227,841	$	233,384	$	658,050	$	666,490

Net revenues generated in our principle operating regions on a reported basis are as follows:



	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2016		December 26, 2015		December 31, 2016		December 26, 2015
United States	$	136,759	$	131,664	$	393,302	$	379,390
Japan	22,319		19,482		58,949		50,406
Europe	38,892		52,453		116,865		150,610
Asia	27,749		27,755		83,125		79,878
Other	2,122		2,030		5,809		6,206
Net revenues	$	227,841	$	233,384	$	658,050	$	666,490

RESTRUCTURING (Tables)

9 Months Ended

Dec. 31, 2016

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following summarizes the restructuring activity for the nine months ended December 31, 2016:



(In thousands)	Severance and Other Employee Costs			Other Costs			Asset Write Down			Total Restructuring
Balance at April 2, 2016	$	8,752		$	—		$	—		$	8,752
Costs incurred, net of reversals	16,680			785			599			18,064
Payments	(16,301		)	(463		)	—			(16,764		)
Non-cash adjustments	—						(599		)	(599		)
Balance at December 31, 2016	$	9,131		$	322		$	—		$	9,453

Schedule of Restructuring and Related Costs

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs	Three Months Ended					Nine Months Ended
(in thousands)	December 31, 2016			December 26, 2015		December 31, 2016		December 26, 2015
Japan	$	(72	)	$	—	$	764	$	9
EMEA	198			37		3,209		155
North America Plasma	1			—		369		—
All Other	1,905			3,829		13,722		18,085
Total	$	2,032		$	3,866	$	18,064	$	18,249

Turnaround costs	Three Months Ended					Nine Months Ended
(in thousands)	December 31, 2016			December 26, 2015		December 31, 2016		December 26, 2015
Japan	$	—		$	142	$	2	$	333
EMEA	(5		)	83		76		503
North America Plasma	37			—		973		—
All Other	4,674			4,295		8,036		10,769
Total	$	4,706		$	4,520	$	9,087	$	11,605

Total restructuring and turnaround costs	$	6,738		$	8,386	$	27,151	$	29,854

COMPREHENSIVE INCOME (Tables)

9 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The components of Accumulated Other Comprehensive Loss are as follows:



(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized Gain/Loss on Derivatives			Total
Balance as of April 2, 2016	$	(22,499	)	$	(7,492	)	$	(5,049	)	$	(35,040	)
Other comprehensive (loss) income before reclassifications⁽¹⁾	(10,344		)	—			1,681			(8,663		)
Amounts reclassified from Accumulated Other Comprehensive Loss⁽¹⁾	—			—			4,678			4,678
Net current period other comprehensive income (loss)	(10,344		)	—			6,359			(3,985		)
Balance as of December 31, 2016	$	(32,843	)	$	(7,492	)	$	1,310		$	(39,025	)

⁽¹⁾ Presented net of income taxes, the amounts of which are insignificant.

BASIS OF PRESENTATION (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015
Basis of Presentation [Line Items]
Correction of understatement for income taxes	$ (1.4)	$ (1.0)
Operating Income (Loss) [Member]
Basis of Presentation [Line Items]
Correction of understatement for income taxes		$ 1.1

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015
Basic EPS
Net income (loss)	$ 15,393	$ (59,440)	$ 24,872	$ (46,844)
Basic weighted average shares (in shares)	51,708	50,741	51,369	50,927
Basic income (loss) per share (in dollars per share)	$ 0.30	$ (1.17)	$ 0.48	$ (0.92)
Diluted EPS
Net income (loss)	$ 15,393	$ (59,440)	$ 24,872	$ (46,844)
Basic weighted average shares (in shares)	51,708	50,741	51,369	50,927
Net effect of common stock equivalents (in shares)	395	0	302	0
Diluted weighted average shares (in shares)	52,103	50,741	51,671	50,927
Diluted income (loss) per share (in dollars per share)	$ 0.30	$ (1.17)	$ 0.48	$ (0.92)
Anti-dilutive shares excluded (in shares)	1,100		1,700

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015
Product Warranties Disclosures [Abstract]
General Warranty Period on Parts and Labor	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 420	$ 531
Warranty provision	860	532
Warranty spending	(1,077)	(701)
Warranty accrual as of the end of the period	$ 203	$ 362

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Apr. 02, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 56,729	$ 56,729	$ 62,062
Work-in-process	10,202	10,202	13,180
Finished goods	121,558	121,558	111,786
Inventories, net	188,489	188,489	$ 187,028
Inventory charges and reserves	$ 4,500	$ 9,000

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015	Apr. 02, 2016
Goodwill [Line Items]
Goodwill impairment	$ 66,300		$ 66,300
Goodwill	267,314		267,314		$ 267,840
Impairment charge	400		1,900
Contingent consideration income	$ 0	$ (4,898)	$ 0	$ (4,727)
Americas Blood Center and Hospital [Member]
Goodwill [Line Items]
Reporting unit, percentage of fair value in excess of carrying amount					25.80%
Goodwill					$ 175,900
SOLX Intangible Assets [Member]
Goodwill [Line Items]
Impairment charge					18,700
Contingent consideration income					$ (4,900)

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2016 USD ($)
Designated as Hedging Instrument \| Cash Flow Hedging \| Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ (1,517)
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	4,678
Designated as Hedging Instrument \| Cash Flow Hedging \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	388
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	165
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ 1,031

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - Designated as Hedging Instrument - USD ($) $ in Thousands	Dec. 31, 2016	Apr. 02, 2016
Derivative Assets:
Derivative Assets	$ 3,324	$ 427
Derivative Liabilities:
Derivative Liabilities	1,916	4,210
Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	3,255	427
Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	1,916	4,056
Interest Rate Swap [Member] \| Other Current Assets
Derivative Assets:
Derivative Assets	69	0
Interest Rate Swap [Member] \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 0	$ 154

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Apr. 02, 2016
Assets
Money market funds	$ 79,452	$ 72,491
Designated foreign currency hedge contracts	3,255	427
Designated interest rate swaps	69
Assets, Fair Value Disclosure, Total	82,776	72,918
Liabilities
Designated foreign currency hedge contracts	1,916	4,056
Designated interest rate swap		154
Liabilities, Fair Value Disclosure	1,916	4,210
Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	79,452	72,491
Designated foreign currency hedge contracts	0	0
Assets, Fair Value Disclosure, Total	79,452	72,491
Liabilities
Designated foreign currency hedge contracts	0	0
Designated interest rate swap		0
Liabilities, Fair Value Disclosure	0	0
Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0	0
Designated foreign currency hedge contracts	3,255	427
Designated interest rate swaps	69
Assets, Fair Value Disclosure, Total	3,324	427
Liabilities
Designated foreign currency hedge contracts	1,916	4,056
Designated interest rate swap		154
Liabilities, Fair Value Disclosure	$ 1,916	$ 4,210

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details)	9 Months Ended
	Dec. 31, 2016 USD ($)	Apr. 02, 2016 USD ($)	Dec. 21, 2012 USD ($) swap
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US	40.00%
Maturity period for foreign currency contracts	1 year
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)	$ 0
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding	99,000,000	$ 107,400,000
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months	1,200,000
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative [Line Items]
Number of interest rate derivatives held \| swap			2
Notional amount of derivative	150,000,000		$ 250,000,000
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Non-designated foreign currency hedge contracts outstanding	49,700,000	$ 48,800,000
Net revenues, COGS, and SG&A \| Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	4,678,000
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ (1,517,000)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015	Apr. 02, 2016
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ 3,544	$ (3,878)	$ 6,839	$ 1,696
Reported tax rate	18.70%	6.10%	21.60%	(3.80%)
Discrete tax provision			$ 1,400	$ 1,000
Statutory capital gains tax rate in Puerto Rico		15.00%		15.00%	20.00%
Goodwill impairment	$ 66,300		66,300
Intangible asset impairment	18,700		18,700
Benefit to income taxes from impairment losses	7,100		7,100
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning balance			2,523	$ 7,070
Additions for tax positions of prior years			1,260	340
Reductions of tax positions			0	(4,158)
Closure of statute of limitations			(403)	$ (729)
Ending balance	3,380		3,380
Unrecognized Tax Benefits, Decreases Resulting from Lapse of Applicable Statute of Limitations			500
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,500		1,500		$ 600
Unrecognized Tax Benefits, Increase Resulting from Potential Tax Impacts of Restructuring			1,300
Decrease in Unrecognized Tax Benefits is Reasonably Possible	1,300		1,300
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 400		$ 400		$ 400

DEBT (Details) - USD ($)			3 Months Ended		9 Months Ended	36 Months Ended
DEBT (Details) - USD ($)	Aug. 01, 2015	Aug. 01, 2012	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Jan. 31, 2017	Jun. 30, 2014
Debt Instrument [Line Items]
Debt outstanding			$ 337,200,000		$ 337,200,000
Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum
Debt Instrument [Line Items]
Interest rate	1.125%
Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum
Debt Instrument [Line Items]
Interest rate	1.50%
Term Loan [Member]
Debt Instrument [Line Items]
Face amount of debt		$ 475,000,000
Principal repayments			$ 11,900,000		30,800,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 50,000,000					$ 100,000,000
Term of credit facilities		5 years
Principal repayments				$ 40,000,000	$ 40,000,000
Revolving Credit Facility [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Principal repayments						$ 10,000,000

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	1 Months Ended		9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Jul. 31, 2016	Apr. 30, 2013	Dec. 31, 2016
Product Recall
Loss Contingencies [Line Items]
Damages claimed			$ 14,600,000
Product recall expense			4,300,000
Product Recall \| Minimum
Loss Contingencies [Line Items]
Estimate of possible loss			600,000
Product Recall \| Maximum
Loss Contingencies [Line Items]
Estimate of possible loss			14,600,000
Product Recall \| Customer Returns and Inventory Reserves [Member]
Loss Contingencies [Line Items]
Product recall expense			3,700,000
Product Recall \| Customer Claims [Member]
Loss Contingencies [Line Items]
Product recall expense			600,000
Product Recall \| Inventories [Member]
Loss Contingencies [Line Items]
Product recall expense			1,100,000
Product Recall \| Sales [Member]
Loss Contingencies [Line Items]
Product recall expense			2,500,000
Product Recall \| Freight Expense [Member]
Loss Contingencies [Line Items]
Product recall expense			100,000
Italian Employment Litigation [Member]
Loss Contingencies [Line Items]
Damages claimed			4,300,000
Amount accrued			0
SOLX Arbitration [Member]
Loss Contingencies [Line Items]
Damages claimed	$ 17,000,000
Amount accrued			$ 0
Payments under previous acquisition		$ 24,000,000
Contingent milestone payment		3,000,000
Maximum future royalty payments		$ 14,000,000
Royalty Term		10 years

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016 USD ($) franchise	Dec. 26, 2015 USD ($)	Dec. 31, 2016 USD ($) franchise	Dec. 26, 2015 USD ($)	Apr. 02, 2016 segment
Segment Reporting [Abstract]
Number of operating segments \| segment					2
Number of franchises \| franchise	4		4
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	$ 233,238	$ 234,563	$ 666,667	$ 665,123
Effect of exchange rates	(5,397)	(1,179)	(8,617)	1,367
Net revenues (reported)	227,841	233,384	658,050	666,490
Effect of exchange rates	(151)	(7)	(790)	3,875
Restructuring and turnaround costs	(6,762)	(8,570)	(27,215)	(29,746)
Deal amortization	(6,530)	(7,389)	(20,611)	(22,193)
Impairment of assets	(210)	(85,048)	(1,525)	(85,048)
Contingent consideration income	0	4,898	0	4,727
Operating income (loss)	21,212	(61,177)	38,125	(38,392)
Plasma [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	108,655	100,578	309,868	282,141
Blood Center [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	76,354	90,418	221,567	257,736
Cell Processing Management [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	25,918	27,741	77,949	83,659
Hemostasis Management [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	16,914	14,647	48,666	42,954
United States
Segment Reporting Information [Line Items]
Net revenues (reported)	136,759	131,664	393,302	379,390
Japan
Segment Reporting Information [Line Items]
Net revenues (reported)	22,319	19,482	58,949	50,406
Europe
Segment Reporting Information [Line Items]
Net revenues (reported)	38,892	52,453	116,865	150,610
Asia
Segment Reporting Information [Line Items]
Net revenues (reported)	27,749	27,755	83,125	79,878
Other
Segment Reporting Information [Line Items]
Net revenues (reported)	2,122	2,030	5,809	6,206
Japan
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	20,173	22,709	53,730	60,212
EMEA
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	49,857	53,258	141,531	150,267
North America Plasma
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	83,324	73,378	235,091	206,427
All Other
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	79,884	85,218	236,315	248,217
Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	73,548	81,420	220,816	232,000
Operating Segments \| Japan
Segment Reporting Information [Line Items]
Operating income (loss)	9,331	10,013	24,335	26,643
Operating Segments \| EMEA
Segment Reporting Information [Line Items]
Operating income (loss)	13,116	13,280	33,866	35,292
Operating Segments \| North America Plasma
Segment Reporting Information [Line Items]
Operating income (loss)	24,660	28,445	80,209	81,909
Operating Segments \| All Other
Segment Reporting Information [Line Items]
Operating income (loss)	26,441	29,682	82,406	88,156
Corporate operating expenses
Segment Reporting Information [Line Items]
Operating income (loss)	$ 38,683	$ 46,481	$ 132,550	$ 142,007

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015	Apr. 02, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Savings	$ 40,000		$ 40,000
Total restructuring and turnaround costs	6,738	$ 8,386	27,151	$ 29,854
Expected cost	26,000		26,000
Restructuring costs	2,032	3,866	18,064	18,249
Restructuring Reserve	9,453		9,453		$ 8,752
Restructuring Charges Payable In Next Twelve Months	9,200		9,200
Turnaround costs	4,706	$ 4,520	9,087	$ 11,605
Global Strategic Review [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	4,100		22,900
Prior Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,600		4,200
Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Expected cost	17,000		17,000
Restructuring costs			16,680
Restructuring Reserve	9,131		9,131		8,752
Other Costs
Restructuring Cost and Reserve [Line Items]
Expected cost	9,000		9,000
Restructuring costs			785
Restructuring Reserve	$ 322		$ 322		$ 0

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015
Restructuring Reserve [Roll Forward]
Balance at April 2, 2016			$ 8,752
Costs incurred, net of reversals	$ 2,032	$ 3,866	18,064	$ 18,249
Payments			(16,764)
Non-cash adjustments			(599)
Balance at December 31, 2016	9,453		9,453
Severance and Other Employee Costs
Restructuring Reserve [Roll Forward]
Balance at April 2, 2016			8,752
Costs incurred, net of reversals			16,680
Payments			(16,301)
Non-cash adjustments			0
Balance at December 31, 2016	9,131		9,131
Other Costs
Restructuring Reserve [Roll Forward]
Balance at April 2, 2016			0
Costs incurred, net of reversals			785
Payments			(463)
Non-cash adjustments
Balance at December 31, 2016	322		322
Asset Write Down
Restructuring Reserve [Roll Forward]
Balance at April 2, 2016			0
Costs incurred, net of reversals			599
Payments			0
Non-cash adjustments			(599)
Balance at December 31, 2016	$ 0		$ 0

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Dec. 31, 2016	Dec. 26, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 2,032	$ 3,866	$ 18,064	$ 18,249
Turnaround costs	4,706	4,520	9,087	11,605
Total restructuring and turnaround costs	6,738	8,386	27,151	29,854
Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs			16,680
Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs			785
Japan
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(72)	0	764	9
Turnaround costs	0	142	2	333
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring costs	198	37	3,209	155
Turnaround costs	(5)	83	76	503
North America Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1	0	369	0
Turnaround costs	37	0	973	0
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,905	3,829	13,722	18,085
Turnaround costs	4,674	$ 4,295	8,036	$ 10,769
Global Strategic Review [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 4,100		$ 22,900

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Dec. 31, 2016	Dec. 26, 2015	Apr. 02, 2016
Research and Development [Abstract]
Capitalized software development costs for ongoing initiatives	$ 8.3	$ 12.9
Software costs capitalized, net	61.9		$ 54.9
Total costs capitalized related to in process software development initiatives	16.9		$ 14.4
Capitalized software development costs placed into service	4.5	$ 6.4
Impairment of capitalized software	$ 1.3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 1) $ in Thousands	9 Months Ended
	Dec. 31, 2016 USD ($)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 2, 2016	$ (35,040)
Other comprehensive income (loss) before reclassifications	(8,663)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	4,678
Net current period other comprehensive income (loss)	(3,985)
Balance as of December 31, 2016	(39,025)
Foreign Currency
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 2, 2016	(22,499)
Other comprehensive income (loss) before reclassifications	(10,344)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	(10,344)
Balance as of December 31, 2016	(32,843)
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 2, 2016	(7,492)
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	0
Balance as of December 31, 2016	(7,492)
Net Unrealized Gain/Loss on Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 2, 2016	(5,049)
Other comprehensive income (loss) before reclassifications	1,681
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	4,678
Net current period other comprehensive income (loss)	6,359
Balance as of December 31, 2016	$ 1,310